Archived Bulletins

October 10, 2018

Published: October 10, 2018
Category: Trials

It is anticipated that RIPPLE (Roster Interface Program and Participants List Environment) version 3.0 will be rolled out on October 19, 2018. 

Read More

Published: October 10, 2018
Category: Trials

Canadian Cancer Trials group is providing an update about the previously planned BI.3 trial "A Phase II/III Trial Comparing Cisplatin Plus Acelarin to Cisplatin Plus Gemcitabine in First-Line Treatment of Locally Advanced or Metastatic Biliary Tract Cancer". The BI.3 trial will not be proceeding to move forward through the planned academic consortium as lead by CCTG, the partnering company has made a strategic decision to undertake the study as an industry-sponsored trial.

Read More

Published: October 10, 2018
Category: Trials
Trial closure: IND.211
The CCTG trial team, is happy to announce that the IND.211 trial has now officially closed. No further ethics approvals or follow-up data are required. The notification of permanent trial closure is posted on the CCTG website in the "Toolbox" and on the IND.211 trial page:https://www.ctg.queensu.ca/docs/trials/permanent_closure/I211-CTG-led-Final%20Letter_to_Cdn_sites.pdf

 

Read More

Published: October 10, 2018
Category: News

Why are cancer clinical trials important? Find out in this video interview with Dr. Rebecca Auer.

Read More

A new trial, Nivolumab, Ipilimumab in Patients With Hyper Mutated Cancers Detected in Blood (NIMBLe) will soon open at centers in the US and Canada. Trial researchers will initially explore the use of non-invasive approaches to confirm POLE and POLD1 mutations in solid tumors and to investigate whether those tumors are responsive to immunotherapy.

Read More

September 26, 2018

Published: September 26, 2018
Category: Trials

IND.210 A Randomized Phase II Study of Reolysin in Combination with FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Al one in Patients with Metastatic Colorectal Cancer

Read More

Published: September 26, 2018
Category: News

On Wednesday September 19th 2018, CCTG's Director, Dr. Janet Dancey aired on the Blind Date with Knowledge radio show. During her interview Dr. Dancey talks about Evolving Clinical Trials through Collaboration. She discussed how the collaborative study of medical interventions in the treatment of cancer has expanded to also investigate how lifestyle, radiation, surgical, and smoke cessation interventions can affect the entire spectrum of cancer treatment.

Read More

CCTG publication

Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, Shalabi A, Siu LL, Tabernero J, Giaccone G. Design and conduct of early clinical studies of immunotherapy agent combinations: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (ONLINE) Ann Oncol mdy398, 2018.

Read More